← Back to Search

Other

Dose-escalation - RL-007 for Schizophrenia

Phase 2
Waitlist Available
Led By David Walling, PhD
Research Sponsored by Recognify Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study day 8

Summary

The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia

Eligible Conditions
  • Schizophrenia
  • Cognitive Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study day 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and study day 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in blood pressure (systolic and diastolic) from baseline
Change in electrocardiogram (ECG) from baseline
Change in heart rate from baseline
+4 more
Secondary study objectives
Change from baseline in amplitude of mismatch negativity (MMN) ERP
Change from baseline in evoked response potential (ERP) amplitude
Change from baseline in evoked response potential (ERP) latency
+2 more
Other study objectives
Category fluency performance
Symbol coding performance
Verbal learning performance

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose-escalation - RL-007Experimental Treatment1 Intervention
Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
Group II: Dose-escalation - matching PlaceboPlacebo Group1 Intervention
Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RL-007
2021
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Recognify Life SciencesLead Sponsor
1 Previous Clinical Trials
234 Total Patients Enrolled
1 Trials studying Schizophrenia
234 Patients Enrolled for Schizophrenia
David Walling, PhDPrincipal InvestigatorCollaborative Neuroscience Research
3 Previous Clinical Trials
324 Total Patients Enrolled
1 Trials studying Schizophrenia
60 Patients Enrolled for Schizophrenia
~8 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top